Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 5, 2012, Pages 727-734

  Farrell, Colm ^a   Schweizer, Charles ^b   Wustner, Jason ^b   Weil, Susan ^b   Namiki, Masayuki ^c   Nakano, Tomohisa ^c   Nakai, Kenya ^c   Phillips, Martin D ^b  

^a ICON CLINICAL RESEARCH   (United States)

^b Morphotek Inc   (United States)

^c EISAI CO LTD   (Japan)

Author keywords

Farletuzumab; Folate receptor alpha; Monoclonal antibody; Ovarian neoplasms; Population pharmacokinetics

Indexed keywords

ANTIBODY; FARLETUZUMAB; FOLATE RECEPTOR 1;

ADULT; AGED; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION MODEL; PRIORITY JOURNAL; SIMULATION; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BODY WEIGHT; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FOLATE RECEPTOR 1; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; NONLINEAR DYNAMICS; OVARIAN NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84871180236     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1959-y     Document Type: Article

References (21)

1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236
2. National Cancer Institute (2011) Seer Stat Fact sheet: ovary. http://seer.cancer.gov/statfacts/html/ovary.html. Accessed 26 April 2011
3. Kalli KR, Oberg AL, Keeney GL, Christianson TJH, Low PS, Knutson KL, Hartmann LC (2008) Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 108: 619-626
4. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M (1997) Overexpression of folate binding protein in ovarian cancers. Int J Cancer 74:193-198
5. O'Shannessy DJ, Somers EB, Albone E, Cheng X, Park YC, Tomkowicz BE, Hamuro Y, Kohl TO, Forsyth TM, Smale R, Fu YS, Nicolaides NC (2011) Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget 2:1227-1243
6. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338:284-293
7. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr, Kamen BA (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52:3396-3401
8. Bottero F, Tomassetti A, Canevari S, Miotti S, Ménard S, Colnaghi MI (1993) Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 53:5791-5796
9. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, Phillips MD, Nicolaides NC, Sass PM, Grasso L (2007) Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-Alpha. Cancer Immun 7:6
10. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16:5288-5295
11. Smith-Jones PM, Pandit-Taskar N, Cao W, O'Donoghue J, Philips MD, Carrasquillo J, Konner JA, Old LJ, Larson SM (2008) Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 35:343-351
12. White AJ, Coleman RL, Armstrong DK, Glenn D, Bicher A, Richards DA, Schneeweiss A, Old LJ, Schweizer C, Weil S (2010) Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: final data from a multicenter phase II study. J Clin Oncol 28(Suppl 15):5001
13. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2 metastatic breast cancer. Cancer Chemother Pharmacol 56:361-369
14. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779-786
15. Ng CM,LumBL, GimenezV, Kelsey S, AllisonD(2006) Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 23:1275-1284
16. Dirks NL,Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633-659
17. Sun YN, Lu JF, Joshi A, Compton P, Kwon P, Bruno RA (2005) Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-Term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 45:468-476
18. Ma P, Yang BB, Wang YM, Peterson M, Narayanan A, Sutjandra L, Rodriguez R, Chow A (2009) Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors. J Clin Pharmacol 49:1142-1156
19. Seitz K, Zhou H (2007) Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol 47:1104-1118
20. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:493-507
21. Boxenbaum H, Battle M (1995) Effective half-life in clinical pharmacology. J Clin Pharmacol 35:763-766